Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib‐treated endometrial carcinoma cells
Open Access
- 7 July 2012
- journal article
- research article
- Published by Wiley in Molecular Oncology
- Vol. 6 (5) , 530-541
Abstract
Sunitinib reduces cell viability, proliferation and induces apoptotic cell death. Sunitinib blocks either basal NFκB activity or induced by different ligands. NFκB pathway mediates the synergistic ...Keywords
Funding Information
- FIS 2010 (PI100922)
- FIS 2006 (PI060832)
This publication has 50 references indexed in Scilit:
- Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: A tangible union against chemoresistant cancerBMC Cancer, 2011
- Identification of known drugs that act as inhibitors of NF-κB signaling and their mechanism of actionBiochemical Pharmacology, 2010
- Proapoptotic Activity of Bortezomib in Gastrointestinal Stromal Tumor CellsCancer Research, 2010
- Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cellsBlood, 2009
- Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid LeukemiaPLOS ONE, 2009
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancerBMC Cancer, 2007
- Molecular Targets in Melanoma from Angiogenesis to ApoptosisClinical Cancer Research, 2006
- Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitorsOncogene, 2005
- NF-κB in cancer: from innocent bystander to major culpritNature Reviews Cancer, 2002